Physicians in Europe are advised to inform their patients about the case of PML in a patient taking Tecfidera according to a medscape article. Reported by Susan Jeffery the article is linked here:
If the link doesn’t work Google the article title, “Inform Patients of PML Case With Tecfidera in MS”
Quoting the article, “The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is advising physicians to inform their patients about a fatal case of progressive multifocal leukoencephalopathy (PML) in a patient being treated with dimethyl fumarate (Tecfidera, Biogen Idec) for multiple sclerosis (MS).
The case is the first of PML reported in association with this oral agent."
"The PRAC recommended that healthcare professionals and patients be informed and considered that there should be further evaluation of this case," a statement from the EMA released Friday noted."
"A spokesperson for the EMA press office said that the brief statement was all the agency is prepared to say about the issue at this time."
"George Scangos, PhD, chief executive officer of Biogen Idec, confirmed the PML case during the company's third quarter investors call October 22." End Quote.
URL removed and will not work unless one has a Medscape Acct.
If the link doesn’t work Google the article title, “Inform Patients of PML Case With Tecfidera in MS”
Quoting the article, “The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is advising physicians to inform their patients about a fatal case of progressive multifocal leukoencephalopathy (PML) in a patient being treated with dimethyl fumarate (Tecfidera, Biogen Idec) for multiple sclerosis (MS).
The case is the first of PML reported in association with this oral agent."
"The PRAC recommended that healthcare professionals and patients be informed and considered that there should be further evaluation of this case," a statement from the EMA released Friday noted."
"A spokesperson for the EMA press office said that the brief statement was all the agency is prepared to say about the issue at this time."
"George Scangos, PhD, chief executive officer of Biogen Idec, confirmed the PML case during the company's third quarter investors call October 22." End Quote.
URL removed and will not work unless one has a Medscape Acct.